01295nas a2200325   4500000000100000008004100001260001700042653001500059653001000074653001600084653001200100653003000112653001100142653002200153653001100175653001200186653000900198653001600207653001300223100001300236700001100249700001700260700001500277245008900292300001000381490000700391050003200398520052500430022001400955       1987                            d  c1987 Jan-Mar10aAdolescent10aAdult10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aFollow-Up Studies10aHumans10aleprosy10aMale10aMiddle Aged10aRifampin1 aKatoch K1 aRamu G1 aRamanathan U1 aSengupta U00aFollow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.  a36-430 v59  aInfolep Library - available3 a<p>56 lepromatous leprosy patients with an initial average BI of 4.45 were administered once a month 600 mg of Rifampicin, 100 mg of Clofazimine on alternate days and 100 mg of Dapsone daily. None of these patients became smear negative in 2 years, and the same regimen was continued further. Two patients have become negative in 3 years and treatment has been stopped in them. The study indicates that highly bacilliferous LL/BL patients are likely to need 3 years or more of MDT for achieving bacterial negativity.</p>  a0254-9395